Aerogen Pharma and Lyomark Pharma have partnered to develop a clinically superior treatment for Respiratory Distress Syndrome (RDS), a life-threatening condition of preterm infants associated with long-term lung health issues in survivors.
A new report from Persistence Market Research expects worldwide cryotherapy market to exceed $4bn by 2024.
bluebird bio and Scottish immunotherapy company TC BioPharm have partnered and signed a license agreement on gamma delta CAR T cells.
Gilead Sciences and its cell therapy subsidiary Kite have agreed to acquire Cell Design Labs, a biotherapeutics company that discovers and develops cell-based therapies, for about $567m.
Fate Therapeutics has partnered with the University of California San Diego to develop off-the-shelf, chimeric antigen receptor (CAR)-targeted natural killer (NK) cell cancer immunotherapies.
Adding aspirin to some existing cancer drugs could increase their effectiveness against a group of tumours resistant to treatment, new research has shown.
Blue Oak Pharmaceuticals and PGI Drug Discovery (PsychoGenics) have entered into a partnership to discover and optimize novel treatments for brain disorders and psychiatric conditions.
Astellas Pharma has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement governing their research and development (R&D) collaboration focused on discovering and developing novel drugs that target mitochondrial function.
I-Mab Biopharma and MorphoSys have entered into an exclusive regional licensing agreement to develop and commercialize MOR202 in China, Taiwan, Hong Kong and Macao.
resTORbio, a clinical-stage biopharmaceutical company engaged in the development and commercialization of novel therapeutics for the treatment of aging-related diseases, has raised $40m in a Series B financing round.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.